March 30, 2023
OMRON Healthcare champions heart health with clinically validated digital blood pressure devices
March 23, 2023
Shinagawa links partnership with Fujifilm Philippines Inc. to advance preventive care in the Philippines
Shinagawa Diagnostic and Preventive Care Center is a subsidiary of Shinagawa LASIK & Aesthetics, the country’s leading Lasik provider
March 23, 2023, MANILA, Philippines – Early detection of diseases can aid in saving lives, giving patients more time to seek effective treatments that help lessen and possibly cure their symptoms. Shinagawa Diagnostic & Preventive Care Center takes this a step further and encourages preventive healthcare by offering more thorough and advanced examinations with the support of Fujifilm Philippines Inc.
(L-R) John Paul Camarillo, Deputy Division Manager of Medical Systems for Fujifilm Philippines Inc., Evan Reyes, Division Manager of Medical Systems for Fujifilm Philippines Inc., Masahiro Uehara, President of Fujifilm Philippines Inc., Masako Uemori, President of Shinagawa Philippines, Raymond Mendoza, MD, DPSP, Medical Director for Shinagawa Healthcare Solutions Corp., Christian Parra, MD, Family Medicine for Shinagawa Healthcare Solutions Corp., and Tahnee Sunga - Vice President of Marketing and Business Development for Shinagawa Philippines
Committed to upholding high standard medical services, Shinagawa announces its partnership with Fujifilm Philippines Inc, an expert in prevention and diagnostics technology, in a signing ceremony today at Shangri-La The Fort. Through the collaboration, Shinagawa’s Diagnostic & Preventive Care Center acquires Fujifilm’s endoscopy equipment to conduct advanced testing for the gastrointestinal (GI) tract, which includes the esophagus, stomach, and small intestine. This helps identify emerging diseases, such as stomach ulcers, gastrointestinal disorders, lung problems, and possibly tumors. The technology eases the detection process as it can spot even the smallest abnormality using endoscopes that place minimal stress on the patient.
“It is of utmost importance to conduct detailed examinations regularly to find diseases at an early stage, leading to preventive care. In particular, Fujifilm's endoscopy equipment enables early detection of diseases that could not be found in advance by general medical checkups in the Philippines, and we believe this will lead to preventive medicine,” said Masako Uemori, President of Shinagawa LASIK and Aesthetics, Philippines.
Fujifilm Philippines Inc guarantees the prime condition and maintenance of equipment to ensure that all examinations produce in-depth results for more accurate diagnosis. The diagnostics technology company will also be conducting a series of training sessions for Shinagawa doctors and staff to fully regulate the use of the machines, assuring safe and accurate examinations. Through the synergy of Shinagawa’s Japanese-standard medical services and Fujifilm’s innovative healthcare equipment, improved quality of life, diagnosis, and prevention are now made more accessible.
The Shinagawa Diagnostic & Preventive Care will have its grand opening this April. Those who are interested in the center may check out Shinagawa’s official Facebook page @ShinagawaDiagnostic or the official website at www.shinagawa-healthcare.ph to book an appointment. Shinagawa Diagnostic & Preventive Care Center is located at Ore Central Tower, BGC.
------------------------------------
ABOUT SHINAGAWA
Being the world leader in LASIK and Aesthetic medicine, Shinagawa takes on a new role this 2023 in diagnostic and preventive care. Shinagawa Diagnostic & Preventive Care is the first one-stop medical hub that offers Japanese-standard health services that provide a wide range of diagnostic tests and customizable screenings by globally competitive medical specialists in bringing convenient, efficient, and affordable preventive diagnostic centers. Through this, the company can pursue its commitment to providing “Health and Well-being for All” and heightening prevention awareness among Filipinos to realize that early detection is better than cure.
October 24, 2022
mWell sets new standards in digital health apps with the Philippines’ first fully integrated platform
- · First health app available globally to migrant workers/OFWs
- · First to offer the most affordable telemedicine with free accident insurance package via the Healthsavers Plan
- · First to launch the biggest nationwide digital medical mission with hundreds of volunteer doctors simultaneously providing free consultation all over the country through the National mWellness Day
- · First to offer a wellness score developed by data scientists--the mWellness Score which measures physical activity, steps, and sleep
- · First to provide a cutting-edge, full suite clinic management system designed by doctors for doctors—mWellMD
- · First to provide a portable mobile digital clinic to remote communities in the country—mWell OnTheGo
October 8, 2022
DKSH and LEO Pharma Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis
Khalid Aouidat, Vice President, Commercial Activities, SEA, LEO Pharma (left) and Bijay Singh, Head of Business Unit Healthcare at DKSH (right) at LEO Pharma's head office in Denmark. |
DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has partnered with LEO Pharma to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia.
Partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam, and the Philippines, the two companies seek to solidify brand presence, grow market share, and ultimately improve patient health outcomes in the region. Skin diseases can cause serious physical and social discomfort for millions of patients around the world whereas thrombosis can affect anyone regardless of their age, race, gender, and ethnicity.
DKSH will support LEO Pharma by building dedicated sales and marketing teams on the ground in Asia and managing logistics and product distribution in these markets. The firm’s experienced teams and broad distribution network will ensure LEO Pharma products reach modern trade, traditional trade, hospitals, clinics, and other medical channels, as well as patients in need across the region.
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. With decades of research and development to advance the science of dermatology, LEO Pharma now offers a wide range of innovative treatments and therapies for all skin disease severities as well as thrombosis.
Khalid Aouidat, Vice President, responsible for commercial activities in Southeast Asia at LEO Pharma commented: “At LEO Pharma, we are dedicated to changing the standards of care for people with skin diseases by bringing new innovative treatments forward and making them easily accessible. Supporting this ambition, we are delighted to be partnering with DKSH. Their experience and strong regional footprint in Asia, as well as their marketing and sales expertise will help to further strengthen LEO Pharma’s brand and its continued growth.”
Bijay Singh, Head of Business Unit Healthcare at DKSH, said: “We are
committed to enriching people’s lives and improving healthcare for all. The
partnership with LEO Pharma strengthens our ambition to become the preferred
partner for clients to help patients in Asia to have better access to
high-quality and innovative products and solutions. While we drive their growth
across the region, LEO Pharma can focus on researching and developing products
and solutions for people with skin conditions.”
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of
care for the benefit of people with skin conditions, their families and
society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma
has devoted decades of research and development to advance the science of
dermatology, and today, the company offers a wide range of therapies for all
disease severities. LEO Pharma is headquartered in Denmark with a global team
of 5,200 people, serving millions of patients across the world. In 2021, the
company generated net sales of EUR 1,339 million. www.leo-pharma.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we
have been delivering growth for companies in Asia and beyond across our
Business Units Healthcare, Consumer Goods, Performance Materials, and
Technology. As a leading Market Expansion Services provider, we offer sourcing,
market insights, marketing and sales, eCommerce, distribution and logistics as
well as after-sales services. DKSH is a participant
of the United Nations Global Compact and adheres to its principles-based
approach to responsible business. Listed on the SIX Swiss Exchange, DKSH
operates in 36 markets with 33,100 specialists, generating net sales of CHF
11.1 billion in 2021. The DKSH Business Unit Healthcare distributes
pharmaceuticals, consumer health and over-the-counter (OTC) products as well as
medical devices. With around 7,920 specialists, the Business Unit generated net
sales of CHF 5.6 billion in 2021. www.dksh.com/hec
September 12, 2022
PH’s fastest-growing app sets the record for the biggest nationwide online medical mission
mWell unites hundreds of doctor-volunteers, mental health experts,
and health-conscious Filipinos on National mWellness Day
Despite hectic schedules, doctors and mental health experts from all over the country willingly donated their time and expertise to provide free consultation via the mWell app. |
Hundreds of patients from across the country were able to consult for free via the user-friendly mWell PH app. |
Advocacy leads: Metro Pacific Investments Corporation Chief Finance, Risk and Sustainability Officer Chaye Cabal-Revilla and MPIC President, Chairman and CEO, Manny V. Pangilinan. |
mWell OnTheGo empowered Dumagats in Brgy Lumutan, General Nakar, Quezon to consult online for free using the mWell PH app. |
April 28, 2021
Smile Train Launches First Filipino Speech Therapy App
For the thousands of babies born with a cleft each year, speech therapy is an essential need. The COVID-19 pandemic, however, has disrupted access to speech therapy services.